First half of 2015: landmark agreement with AstraZeneca and strong financial position

• Landmark co-development and commercialization agreement with AstraZeneca for IPH2201 in immuno-oncology

• Cash and cash equivalents amounting to €279 million  following initial payment of $250 million from AstraZeneca

• Programs progressing as planned; first clinical data on lirilumab expected in 2016

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) reports today its consolidated financial results for the first half of 2015.
Hervé Brailly, Chief Executive Officer of Innate Pharma, commented: “This first half of 2015 marked a major milestone in Innate Pharma’s corporate development with the signature of a landmark co-development and commercialization agreement in April with AstraZeneca to broaden and accelerate the development of IPH2201.
This agreement is a major step towards our corporate goal of further maturing the Company and developing capabilities in late stage development and potential commercial stage by keeping some co-development and co-promotion rights.
In the second half of 2015, additional Phase II clinical trials for IPH2201 will be opened and IPH4102 will start a multi-centric Phase I trial, becoming our third first-in-class, clinical-stage asset. With our increased financial flexibility, we are intensifying our efforts in R&D to enrich our pipeline of first-in-class proprietary antibodies.
As important new clinical data on lirilumab is generated, Innate Pharma is on track to leverage its unique positioning in the very promising area of immuno-oncology.”

A conference call will be held today at 2:30pm (CET)

Dial in numbers: France: + 33 01 70 77 09 37 / International: +1 855 402 77 61

A replay is available in the “Innate Live” section.